COMPENDIUM

Independent equity research and deep-dive due diligence specializing in biotechnology and healthcare markets.

All Publications • Companies Index • Pipeline Directory

Platform Intelligence Indicators

3

Analysis Reports

Peer-reviewed publications

33

Pipeline Assets

Tracked therapeutic compounds

9

Active Targets

Ingested biological mechanisms

17

Business Profiles

Monitored corporate issuers

Latest Research Analyses

ALT BMEA

Metabolic Disruption: Comparative Mechanistic Positioning of Pemvidutide and Icovamenib

An objective evaluation of alternative clinical paradigms in metabolic disease, comparing Altimmune’s GLP-1R/GCGR dual agonist pemvidutide with Biomea Fusion’s glucose-responsive menin inhibitor icovamenib.

Read Full Analysis →
RADX ATNM

Targeted Radiopharmaceuticals: Comparative Clinical Milestones of 177Lu-RAD202 and Iomab-B

An objective review of recent clinical data for Radiopharm Theranostics' 177Lu-RAD202 and Actinium Pharmaceuticals' Iomab-B, evaluating efficacy metrics, safety profiles, and developmental progress.

Read Full Analysis →
CCCC

Targeted Protein Degradation: Comparative Clinical Milestones of Mezigdomide and Cemsidomide

An objective review of recent clinical data for Bristol Myers Squibb's mezigdomide and C4 Therapeutics' cemsidomide in relapsed/refractory multiple myeloma, evaluating efficacy metrics, safety profiles, and developmental progress.

Read Full Analysis →